LYUMJEV
(Lyumjev)Phase 3Small molecule
Eli LillyLYUMJEV is one of 35 small molecule programs targeting Type 1 Diabetes. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
34
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
79 competitors in Type 1 Diabetes
#DrugCompanyPhaseTrials
1Ozempic
Novo NordiskPhase 3
Stelara
Johnson & JohnsonPhase 3
Inpefa
LLexicon Pharmaceuticals
Phase 3
Tricor
JJagotec
Phase 3
Diamox
TevaPhase 2
Humira
NovartisPhase 2
Kerendia
BayerPhase 2
Teplizumab
SanofiPhase 3
Prolia
OOrganon and Co
Phase 2
Bacillus Calmette-Guérin
Bristol-Myers SquibbPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 1 Diabetes1 trial
A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes
Recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 2/3·NCT06046417·30 enrolled
Regulatory
FDA Approval Timeline[4]
Jun 15, 2020
LYUMJEV
BLA BLA761109
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lyumjev. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]